Company Overview
About Isabl
Isabl is a New York-based whole-genome and transcriptome cancer diagnostics company — backed by Y Combinator (W20) with $5 million in total funding including $3 million from Two Sigma Ventures, BoxOne Ventures, Bossa Invest, and Jude Gomilla, plus a $2 million SBIR grant from the National Cancer Institute (NCI) — commercializing the Isabl GxT (Genome x Transcriptome) diagnostic platform that received FDA Breakthrough Device Designation for comprehensive tumor profiling that analyzes entire tumor genomes and transcriptomes simultaneously to identify cancer-associated mutations, fusion genes, and expression patterns that guide treatment selection. Founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015-2019, Isabl's genomic testing platform is specifically advancing through March 2025 NCI funding for pediatric and rare solid cancers where comprehensive genomic profiling can identify targeted therapy opportunities that standard panel tests miss.
Business Model & Competitive Advantage
Isabl's whole-genome and transcriptome sequencing approach (WGS + WTS) generates more complete tumor genomic information than the targeted gene panel tests (which analyze 50-500 genes) that currently dominate clinical genomic oncology testing: WGS captures all 3 billion base pairs of the tumor genome (detecting structural variants, copy number alterations, mutational signatures, and tumor mutational burden) while WTS captures gene expression across all 20,000+ human genes (identifying fusion transcripts, expression-level changes in cancer driver pathways, and RNA-level splicing variants that DNA sequencing alone misses). The FDA Breakthrough Device Designation (granted for rare and pediatric cancers where comprehensive profiling is most needed) provides the regulatory framework for accelerated FDA review of the Isabl GxT platform as a companion diagnostic. The MSK Cancer Center incubation (one of the world's leading cancer research and treatment institutions) provides the clinical validation context that oncology diagnostic company formation requires.
Competitive Landscape 2025–2026
In 2025, Isabl competes in the cancer genomics diagnostics, comprehensive genomic profiling, and precision oncology market with Foundation Medicine (FDA-approved CGP tests, Roche subsidiary), Tempus AI (NASDAQ: TEM, AI-enabled precision medicine, $1.1B IPO 2024), and Guardant Health (NASDAQ: GH, liquid biopsy and CGP, $1.9B raised) for oncology tumor profiling and comprehensive genomic testing adoption. The NCI SBIR grant (competitive federal funding awarded to early-stage biomedical companies for high-priority cancer research) validates Isabl's scientific approach and provides non-dilutive capital for the pediatric oncology program development. Two Sigma Ventures' investment (quantitative finance and data science firm with deep computational biology conviction) reflects the machine learning integration in Isabl's genomic data analysis pipeline. The 2025 strategy focuses on clinical validation studies for the Isabl GxT in pediatric solid tumors, expanding the NCI partnership for rare cancer genomic profiling programs, and building the clinical laboratory infrastructure for CLIA-certified commercial testing.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Isabl is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare Isabl with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Isabl? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Isabl Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Isabl vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →